Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

AN2 Therapeutics Q3 2026 Results: Net Loss of $8M, Loss Narrows

For the nine months ended September 30, 2026, AN2 Therapeutics reported a net loss of $26.2 million, a slight improvement from the $26.5 million loss in the prior year. Total assets increased to $82.0 million from $62.0 million at year-end 2025, primarily driven by an increase in short-term and long-term investments following a private placement of common stock.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-8.0-9.4
EPS (diluted, $ a share)$-0.17$-0.31

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ANTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

AN2 Therapeutics, Inc.: key numbers

Share price
$4.47Close, Nov 16
Market cap
$170M
Shares outstanding
37.94MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from AN2 Therapeutics, Inc.

All →
7:32 AM ET 8-K
Financial Results

AN2 Therapeutics Financial Results

AN2 Therapeutics reported financial results for the third quarter of 2026, highlighting a net loss of $11.4 million and a cash position of $51.4 million. The company is advancing its clinical pipeline, including the expected year-end enrollment initiation for its Phase 2 study of epetraborole in polycythemia vera and the selection of a new development candidate for hypophosphatasia.

Term
Q3 2026

“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform. With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities.”

Eric Easom, Co-Founder, Chairman, President and CEO

“Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas.”

Eric Easom, Co-Founder, Chairman, President and CEO
6:22 PM ET Form 4
Insider Selling

AN2 Therapeutics Insider Joshua M. Eizen Sells $11.9K of Stock

Joshua M. Eizen sold 2,826 shares of AN2 Therapeutics, Inc. at $4.22 a share, worth $11.9K in total on Nov 5, 2026. Shares held after the trade: 207,546 (-1.3%).

Value
$11.9K
Shares
2,826
Price
$4.22
Holding change
-1.3%
Trade date
Nov 5, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.